Half Year 2025 Chemometec A/S Earnings Call Transcript
Key Points
- ChemoMetec AS (OCSE:CHEMM) reported financial results in line with expectations, maintaining guidance for the full fiscal year.
- The company is set to launch four new instruments by the end of the calendar year, which are expected to unlock significant opportunities in the bioprocessing market.
- Sales from services grew by double digits, indicating strong demand in this segment.
- The company has established a new executive leadership team to focus on growth and strategic priorities.
- ChemoMetec AS (OCSE:CHEMM) has implemented a code of conduct and conducted an employee engagement survey with positive results, reflecting a commitment to ESG initiatives.
- Revenue for the first half of the fiscal year declined by 17% compared to the previous year, with a significant drop in instrument sales.
- The EBITDA margin decreased from 60% to 47% due to lower revenue and increased costs.
- The company faces a challenging funding environment in the cell and gene therapy market, with a minor decrease in global funding.
- Despite new product launches, the market for cell and gene therapy remains subdued, impacting overall growth prospects.
- ChemoMetec AS (OCSE:CHEMM) has not historically implemented price hikes, but recent increases may affect customer demand.
Hello. I would like to welcome everybody to our Chemometec webcast where we will present the half-year financial results from our fiscal year '23, '24.
My name is Rasmus Kofoed As of August last year, the CEO of the company, so now 6 months old in the organization.
We expect our presentation today will take approximately 15 minutes.
Where we will present a business update and the financial results followed by Q&A where we will take any questions you might have either via the phone or webcast.
As all of please be aware of our disclaimer around forward-looking statements.
And today's speakers is myself as well as our group Chief Financial Officer Niels Høy Nielsen .
As a short introduction and for those of you not familiar with Chemometec, we are one of the global leading players providing high quality equipment and services within the field of cell counting and analysis of cells.
The company was founded almost 30 years ago in Denmark by three founders. Historically, Chemometec primary market has been
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
